Long-acting HIV drugs advanced to overcome adherence challenge.
Elie
E
Dolgin
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D055118:Medication Adherence; D009570:Nitriles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068696:Rilpivirine; D054659:Diketopiperazines
D019380:Anti-HIV Agents; D003692:Delayed-Action Preparations; D009570:Nitriles; D011728:Pyridones; D011743:Pyrimidines; D000068696:Rilpivirine; C584914:cabotegravir; D054659:Diketopiperazines